Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study

J Gumprecht, M Benroubi, V Borzi, R Kawamori, J Shaban, S Shah, M Shestakova, Y Wenying, R Ligthelm, P Valensi, IMPROVE Study Group Expert Panel, J Gumprecht, M Benroubi, V Borzi, R Kawamori, J Shaban, S Shah, M Shestakova, Y Wenying, R Ligthelm, P Valensi, IMPROVE Study Group Expert Panel

Abstract

Aims: The international IMPROVE observational study investigated the safety profile and effectiveness of biphasic insulin aspart 30/70 (BIAsp 30) in the routine treatment of patients with type 2 diabetes. We present analyses for the subgroup of patients who switched from basal insulin to BIAsp 30.

Methods: Patients in routine care who started insulin therapy with or switched to BIAsp 30 from existing insulin regimens were eligible for this 26-week study. This analysis includes only patients previously treated with basal insulin. Outcomes including adverse events, hypoglycaemic events and glycaemic profile were recorded from patients' notes, recall and diaries.

Results: Of the 748 patients included (age 59.7+/-11.8 years, diabetes duration 11.4+/-7.3 years, baseline HbA1c 9.1+/-1.6%), 497 were previously using human neutral protamine Hagedorn (NPH) insulin and 245 analogue basal insulin. Overall, major and minor hypoglycaemia rates decreased from baseline to final visit (major: 0.171 to 0.011; minor: 9.70 to 5.89 events/patient-year) and were similar between the subgroups. HbA1c and fasting blood glucose were significantly reduced from baseline (NPH prestudy: -1.6%, -2.4 mmol/l; analogue basal prestudy: -1.8%, -2.4 mmol/l), as was postprandial blood glucose, with 33.8% of patients achieving the HbA1c target < 7% without hypoglycaemia. Insulin dose increased slightly from prestudy (0.33+/-0.21 U/kg), baseline (0.40+/-0.20 U/kg) to final visit (0.52+/-0.26 U/kg); most patients (76%) followed a twice-daily regimen at final visit. Body weight did not change significantly and treatment satisfaction increased.

Conclusions: Patients with type 2 diabetes inadequately controlled on basal insulins may improve their glycaemic control by intensification to BIAsp 30 therapy.

Trial registration: ClinicalTrials.gov NCT00659282.

Figures

Figure 1
Figure 1
Rates of major and minor hypoglycaemia at baseline and final visit, according to prestudy basal insulin therapy

References

    1. Wright A, Burden AC, Paisey RB, et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57) Diabetes Care. 2002;25:330–6.
    1. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet. 1998;352:837–53.
    1. Mudaliar S, Edelman SV. Insulin therapy in type 2 diabetes. Endocrinol Metab Clin North Am. 2001;30:935–82.
    1. Stratton IM, Adler AI, Neil AW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;32:405–12.
    1. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2008;31:1–11.
    1. Hirsch IB, Bergenstal RM, Parkin CG, et al. A real-world approach to insulin therapy in primary care practice. Clin Diabetes. 2005;23:78–86.
    1. Brunton S. Insulin regimens for type 2 diabetes mellitus. J Fam Pract. 2006;55:10S–17S.
    1. Philis-Tsimikas A, Charpentier G, Clauson P, et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther. 2006;28:1569–81.
    1. Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study) Diabetes Obes Metab. 2006;8:58–66.
    1. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c) Diabetes Care. 2003;26:881–5.
    1. Garber AJ, Ligthelm R, Christiansen JS, Liebl A. Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes Obes Metab. 2007;9:630–9.
    1. Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes. A comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260–5.
    1. Malone JK, Kerr LE, Campaigne BN, et al. for the Lispro Mixture-Glargine Study Group Combined therapy with insulin lispro mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomised, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther. 2004;26:2034–44.
    1. Kann P, Wascher T, Zackova V, et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes. 2006;114:527–32.
    1. Wenying Y, Qiuhe J, Dalong Z, et al. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs. Diabetes Care. 2008;31:852–6.
    1. Gough S. Post-marketing surveillance: a UK/European perspective. Curr Med Res Opin. 2005;21:565–70.
    1. Ligthelm RJ, Borzì V, Gumprecht J, et al. Importance of observational studies in clinical practice. Clin Ther. 2007;29:1284–92.
    1. Jang HC, Guler S, Shestakova M, PRESENT Study Group When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study. Int J Clin Pract. 2008;62:1013–8.
    1. Valensi P, Benroubi M, Borzi V, et al. on behalf of the IMPROVE™ Study Group Expert Panel The IMPROVE™ study – a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. Int J Clin Pract. 2008;62:1809–19.
    1. Brod M, Skovlund SE, Wittrup-Jensen KU. Measuring the impact of diabetes through patient report of treatment satisfaction, productivity and symptom experience. Qual Life Res. 2006;15:481–91.
    1. Liebl A, Prager R, Binz K, et al. PREFER Study Group Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER study: a randomised controlled trial. Diabetes Obes Metab. 2009;11:45–52.
    1. Barnett A, Begg A, Dyson P, et al. Insulin for type 2 diabetes: choosing a second line insulin regimen. Int J Clin Pract. 2008;62:1647–53.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit